Geron Corp. (GERN) is expected to host a conference call on April 10th to provide an update on the ongoing phase II/III trial Imetelstat in myelodysplastic syndromes and the phase II Trial in myelofibrosis.
from RTT - Biotech http://ift.tt/2nYyTWW
via IFTTT
No comments:
Post a Comment